Just hold on, to the end for that. Now, if you have any questions, please use the question submission feature, and I'll address as many as I can live in this session. Then any that I can't get to, I'll answer after the session in the Investor Hub platform. So I'll quickly move past the disclaimers, and let's get straight into it. Okay. Now, closing out the first half of FY26, we are continuing to execute on plan and tracking to our target and guidance, expanding clinical adoption in Australia and the United Kingdom, moving up the customer adoption curve, and developing this major new diagnostic category of clinical microbiome testing, delivering strong growth for our core testing products, and tracking to our regional break-even objectives for Australia and the United Kingdom, and that's all on path to break even for the whole company. So let me break down the strong top-line numbers from the quarter. The headline number is core test volume up 90% year-on-year, now at an annualized run rate of over 21,300 and remaining on track for our regional break-even guidance for core test volumes, targeting over 24,000 for the financial year. Aligned to this, Microbiome Explorer now represents 55% of total revenue as we've completed the wind-off and replacement of our legacy product revenues. And this is the breakdown here. So we have our core testing products in the growth category at the top, showing consistent half-on-half revenue growth, up over 120% year-on-year, 129%, in fact. Base product revenues are down a bit for the half as we accelerate transition of our UK nutritional supplements business to our high-margin, owned, and branded products. That's for the half, but the numbers were actually up for the quarter as a result of our strategy. So I'll speak more to that in a minute. And legacy product revenue now winding completely off, and this has been a strategically important transition, so very pleased that this is now complete and in how this is translating to growth at the top there. Aligned to that, we replaced over AUD 1.6 million of legacy product revenue for the quarter, and from the new quarter in Q3, we'll start to see raw revenue growth reflected at the top without the counteracting removal of legacy product revenues. On the cost side, net operating cash flows reduced with disciplined cost management and our operating expenditure reductions implemented in Q2, flowing through to deliver a full quarter of benefit there. A quick reminder here for everyone on the reference to growth, base, and legacy products. The growth products are our, our core tests, opening up this major new diagnostic category with accelerating sales. Base products include our nutritional supplements business in the UK and strategic international partners, which are expected to remain relatively stable with potential for future growth. Although we've had some temporary impact here with the transition we're going through within the supplements business, and again, speak more to that in a moment. The legacy products and services, which have now been fully discontinued, our non-clinical testing products, superseded by our core clinical testing products at the end of Q2. If you have any questions on this transition, we did a deep dive on our diagnostic strategy in March last year. All of those materials are publicly available, but now we've finished this critical strategic transition. We won't need to break the numbers down like this moving forward. As always, there were a range of milestones and highlights from the quarter, so I'm just gonna go through them one by one. And at the start here, I really wanted to pause for a moment and focus that Microba is creating an entirely new diagnostic category in clinical microbiome testing, and we estimate that that category represents a market worth over $100 billion. We have shared in depth that category creation here requires disciplined execution aligned to the customer adoption curve, progressing from innovators into early adopters, and over time, to broader mainstream adoption in the early and late majority. Microba's strategy is designed in a way to de-risk this process through a structured region-by-region market development process that has some distinct stages to it, which we've laid out here in the table. I've been talking about this since early last year, but really thought it was worthwhile laying out very clearly how we've been advancing and what's the progress that we've made. In each major geography, Microba has begun with a non-clinical market entry phase, and that's focused on engaging innovator customers, building key opinion leader relationships, generating initial awareness, and establishing regional healthy reference ranges for our tests. That phase has been completed in Australia and the United Kingdom and is progressing in the United States and Europe through our strategic partnerships there. We've now transitioned into clinical testing. So in Australia, this phase commenced in April 2023 with innovator clinicians and has now successfully progressed into the early adopter uptake. In the United Kingdom, clinical testing began in May 2025, and is currently advancing through that innovator phase. So in Australia, now adoption has moved beyond innovators and into early adopters. This is now including enterprise-style contracts for the first time with small to medium healthcare groups, and since November last year, Microba has now signed 12 clinic account contracts in Australia, representing meaningful recurring volume potential. And we expect that this shift to these larger contracted accounts will continue to accelerate revenue growth ahead, while improving sales efficiencies through higher average revenue per account. Focusing on the U.K., we wanted to zoom in on our progress in our stage market development there, leveraging our existing acquired customer base. In particular, I wanted to ensure that people didn't look at the slightly lower Q2 result and think that that was unexpected or trending in the wrong way. What I've done on these charts is compared Microbiome Explorer Comprehensive volume since launch in Australia, against volume since launch in the United Kingdom. The two key take homes here from these charts is, first, the quarterly trend is the same. The products were actually launched at the same time of the year, so the seasons line up. We saw the same trend between the third and fourth quarters post-launch, which is Q1 to Q2 of the financial year, with the run into Christmas holiday period. Second, we're seeing UK adoption outperform Australian adoption by 33% at the equivalent time post-launch. So this is exactly what we expected to see, leveraging the existing acquired customer base in the UK, and we expect that to continue to accelerate across 2026. I've also recently had multiple shareholders reach out asking, "How are we applying AI in the business?" So I thought that was worth including a good summary with some real tangible examples in the quarterly. And the key message here from me is that we're implementing it across all business functions. We're doing a lot already. We also have a lot on the roadmap, but here are just three tangible examples delivering measurable, measurable efficiencies. First is the implementation of an AI-powered customer support agent, and that's successfully resolved over 70% of customer inquiries autonomously, but impressively doing that with an over 90% customer satisfaction score. So that really plays into our commitment to seamless, responsive customer service, is a real key differentiator for us and drives significant resource efficiency. Second, in software engineering, AI assistance has increased engineer pro-productivity already by 1.5x, and expected to further increase to over 3x across the year, enabling faster development cycles and faster shipping of those new product feature releases. And third, AI model implementation for our scientific literature review and grading, which is really core to our product, and we've already slashed our required human hours there by 30% and on track to surpass 50% reduction soon. That frees up valuable resources for higher value product and evidence generation activities within that team. And so these are just some examples, not exhaustive of everything that we're doing, and we're just at the beginning of our comprehensive AI rollout that really spans all access of the business. Next, product feature releases. So as I've continued to stress, there is an intimate linkage between product advancement, the adoption curve, and our growth strategy. Aligned to that, we continue to update the market on our product advancements and new feature releases, and we had three key feature releases in the last quarter. The first here is the oral species biomarker. That assesses oral microbe species detected in the gut. In short, if you're healthy, these oral microbes shouldn't be in the gut. If you find them there, it can be a sign of issues with stomach acid, commonly associated with PPI, proton pump inhibitor use, and is a key marker of intestinal inflammation. So this is very valuable for clinicians. So this biomarker reports on over 410 oral species, powered by our Oral Species Index, and it's now included in all Microbiome Explorer reports. The second is pay on invoice. So this supports our enterprise sales workflows and adoption from those small, medium, large clinics, which I spoke about before, as we've moved into that earlier adopter segment. So these high volume clinics can now sign a service agreement with Microba and access 30-day payment terms on invoice for all referred and sold tests, which is their preferred way of working. So that's already driven strong conversion of high volume target healthcare professionals and their clinics since we released this, and the sales team have a whole pipeline of clinics that they're working through with high recurring volume potential. The third is Sunday collection and simplified instructions. One of our key focuses is on quality and rigor of our results, and that requires careful temperature management for samples in transit, which has limited the number of days that patients can actually return their samples during the week. So the team have implemented a range of operational changes so that patients can now collect and return their samples on a Sunday, which they couldn't do before. That expands the sampling window, removes a key point of friction in the return process, and improves confidence for patients. Oh, sorry, convenience for patients, I should say. We also implemented simplified instructions and improvements to all of our sampling kits. That reduces sampling complexity, makes that sampling process easier, and actually reduced component costs by about 18%. And the early feedback from all of these improvements have been very positive from both patients and clinicians. Also, I want to update on the major consolidation of our testing brands, which was successfully released in November. So, as I've stated before, through time, we had amassed a range of brands, Microba, Co-Biome, Invivo, and then down at the product level, MetaXplore, MetaPanel, and all of that for our testing business has now been consolidated down to one single brand, Microba. And importantly, that was not about a fresh coat of paint on the house. There was some of that naturally in the updates to logos and colors that you can see on the screen, but that's an artifact of the process, not the purpose of the process. The purpose of the process was all about operational efficiency and increased marketing effectiveness, and that's what's already been delivered here. The entire marketing engine and all of our surfaces have been rebuilt to drive more sales, more cost effectively at scale. And a first real example of this delivering results is our streamlined global lifecycle marketing under the new brand, which has already delivered a shortening of time from practitioner sign-up to a practitioner making their first referral. That's gone from 12.4 days in November, when we released and started to implement this global lifecycle marketing, down to 1.7 days in January. That's a huge result, and there's much more to come there. As a part of the new Microba brand launch, we refreshed our product names to make them simpler, clearer, and more self-describing. So MetaXplore is now known as Microbiome Explorer, which is available in its three variants: Microbiome Explorer Comprehensive, which is available in Australia and the United Kingdom, and then Microbiome Explorer Essentials and Extended, which is available in Australia and coming to the UK in this quarter. So now let's break down those sales results. First, it was another record quarter for MetaXplore in Australia. So we saw continued strong growth, Q1 sales of 4,360 tests, which was up 90% year-on-year, amounting now to an annualized run rate of over 17,400 tests. Ordering clinicians for the quarter reached 878. I've shown these charts here, as I always do, half on half, because it really shows the continued, consistent stepping up in volumes without any seasonal impacts, and also shows here now how we're getting higher volumes per clinician as we move up the adoption curve. In the U.K., as I said before, we're making good progress, 33% higher than the equivalent time post-launch in Australia, leveraging our acquired team and customer base there. Again, I believe it's important here to always look at these numbers half on half, avoid those seasonal lumps and bumps, and here you can see things continuing to trend up nicely as we develop the market there. MetaPanel adoption remaining steady in Australia. As I've stated for multiple quarters, this is not a key growth focus right now. We remain in an early market development phase for this test, focused on development of gastroenterology specialists and key clinical studies that we're executing. So, it's really from FY 2027, where we see the opportunity for larger volume through our KOL and evidence generation work, creating the base for us to then translate that into broader clinical adoption and routine referral behavior. Now to our base category, so that's in particular our UK supplements business. So for our UK supplements business, we have continued to accelerate the transition to a greater focus on our higher margin Invivo-branded and owned supplements versus the third-party distributed Designs for Health-branded products. That delivered a record quarter for our Invivo supplements, and underpinning that was a focus on our evidence-based PHGG prebiotic fiber supplement, where we saw volume up 110% year-on-year. But there were some other good signals here as well. We launched for the first time a subscription offering in October, and it's already grown to over 300 subscribers. We also, with a focus on our work on Amazon, we moved from 99 to twelfth position since September in the fiber, fiber supplement category on Amazon in the UK. So making some good progress here, but much more to come on the UK supplements business over coming quarters. Wrapping up the sales results, I just want to quickly bookend the legacy products. So good news, we have now completed our strategic discontinuation of legacy revenue to focus on our core testing products, which is delivering to plan. During the quarter, the company replaced over AUD 1.6 million of discontinued legacy product revenue, and from this new quarter in Q3, this will enable a clear revenue growth picture, which is great. Now, an update on therapeutics, which is the attractive upside to Microba, leveraging our leading databank and years of R&D. From our data here, we've developed our rich pipeline of therapeutic assets. We've moved from our R&D and investment phase into our partnering focus phase, so we are focused and active in partnering. And the microbiome therapeutic modality here, and more specifically, the live biotherapeutic modality, has really been maturing in its development. So many prospective partners, big pharma, big biotech, have been awaiting definitive phase Ib, phase IIa efficacy data that will validate this new live biotherapeutic modality in a major chronic disease setting, to then support in-licensing or acquiring these assets for their portfolio. So aligned to that, we've been guiding on clinical trial readouts that will provide that modality-validating data for partners and stimulate sector deal activity for microbiome therapeutic assets, including Microba's best-in-class assets that are ready to capture that deal activity. So there have been multiple validating results since November. Siolta Therapeutics first, in November, delivered a successful phase Ib in pediatric allergy disease, a significant result for the sector. Then MaaT Pharma, in December, delivered a major phase III result in gastrointestinal acute graft versus host disease, and that's actually now under regulatory review by the European Medicines Agency for market approval, with a decision expected later this year. So this is a major advancement forward, as that stands to be potentially the first market approval for a microbiome therapeutic in a chronic, non-infection setting. And finally, EnteroBiotix, in January, delivered a positive phase IIa result in irritable bowel syndrome patients. And so now we're waiting for the results from Microbiotica, which are delayed, but expected sometime early this year. So this is all very good news. We've been. We've seen these results really start to change the temperature of partnering discussions at the end of the year and into the new year, and we're very active in our partnering work, leveraging all of this validating sector momentum. Obviously, a transaction here would be expected to have a material impact on the valuation of Microba. So to close out, what's our focus and upcoming catalysts? In diagnostics, we're focused on continued growth in test sales and clinical adoption across Australia and the United Kingdom, continued Microbiome Explorer feature releases supporting that growth. We have some major product advancements scheduled to ship in this quarter, and the launch of the additional Microbiome Explorer SKUs in the UK. In therapeutics, we are active in partnering off the back of the recent positive sector trial readouts, which I just spoke to, and we have the Microbiotica results expected soon. Aligned to our FY 2026 guidance, we would advance towards our regional breakeven milestones in Australia and the UK, all supported by over 100% year-on-year growth in core test volume, targeting over 24,000 tests for the full financial year. That closes the quarterly update, and that sets up for me now to go on to some of the submitted questions that I could see that have come through. Remember, the ones that I don't get to live, I'll ensure that I answer on Investor Hub, as quickly as possible. Also a reminder, anyone new to Microba, I'll do a quick recap on the business, after addressing, a couple of questions here. So I'm just going to go from the top, with the first one here, which is, "Microbiome therapeutic sector readouts, or the microbiome therapeutic sector readouts look really positive and start to provide that validation pharma partners are looking for. What's inhibiting a deal?" Well, we have seen those results translate into active partnering discussions, but deals don't happen overnight. There are more readouts coming, like the one from Microbiotica, but there are some others, so we are seeing some moving a little slowly until either first deals from the early movers start dropping or these additional results come through, which make it unequivocal. Achieving a deal for our therapeutic assets, particularly MAP315, be rest assured, is a top priority. So having those assets valued, we would expect to have a material impact on the share price for shareholders, and set the foundation for realizing the true value of the therapeutic platform that we've built there. The second question here, "Growth seems to be slower in the UK than expected, given the acquisition. Why haven't we seen all of those, Invivo customers switch from the legacy EcologiX products to Microbiome Explorer if the product is that superior?" Now, that's a good question. That's why I put those charts in. So I'm gonna actually go back to that slide. Let me just go back up here, and I'll give a little bit more color and context. Great. So, we acquired Invivo Healthcare because of their established customer base and operations in microbiome testing in the UK. The rationale of that acquisition was that that would enable us to move faster in entry and growth of Microba's advanced clinical testing products than setting up from scratch, and faster than what we had delivered in Australia. Now, in Australia, we didn't start from scratch either when we launched those clinical products. So we had many years in market with our non-clinical insight testing first and had established a base of healthcare professionals. Post-launch of our clinical product in Australia, we saw some rapid initial switching, then a bit of digestion period as people educated and wrapped their head around the new clinical testing products, and we had some seasonal impacts running into Q4, into Christmas and then kicking off the new year. So that was the profile that I was explaining there, Q3, Q4 post-launch. You got to appreciate that the Microbiome Explorer test is very different than what came before in those non-clinical tests, and it changes a lot about how a practitioner works with their patients. And then we saw a real ramp-up of conversion from existing and new accounts into Q5 and Q6 post-launch, in Australia. And so then you can see what played out in the gray bars, after that in Australia. So we're seeing, the same process play out here in the UK, but faster with that acquired customer base in the UK. Last quarter being 33% higher than the equivalent time post-launch in Australia. And this is not just a population effect either. So in the innovator and early adopter segment, the market sizes are actually similar in Australia and UK, given their respective states of familiarity with microbiome testing. But then the jaws open up with a larger market in the UK when we get into early and late majority. So I hope that's helpful. Next one. With the 4C indication of quarters of cash, how should we think about that and runway? Sales and contribution margins are going up and costs are coming down. And I think I said the same thing last quarter. So operating expenditure has been reduced versus same time last year, and we're making good progress on cost of goods. On top of that, there are therapeutic deal opportunities, which I've just highlighted with the backdrop of all of that sector activity, and there are multiple other non-dilutive funding opportunities that we're working on, which can significantly impact the cash position. So stay tuned for more on all of that. The next one is, can you explain the transition of the UK supplements business to the higher margin Invivo-owned and branded products? Yeah, I'm gonna go to that slide actually, and then I will give it a bit more color. Great. So when we acquired Invivo Healthcare, the supplement part of the business had two parts. It had a distribution right to sell a brand called Designs for Health, which is a respected U.S. clinician brand in the U.K., which they'd been selling for many years. They also had a compelling but relatively new portfolio of well-formulated, evidence-based Invivo-owned and branded supplements. So now we're prioritizing our higher margin Invivo branded products over the third-party Designs for Health products. It's more strategic, and there's a bigger opportunity there for us. We're accelerating that transition, which is delivering results, which I went through before, but it does have a short-term impact on overall revenue growth, and so we've been managing that very carefully. As a result of that focus, we delivered, though, a record quarter for our Invivo products. We had our leading PHGG prebiotic supplement up 110% year-on-year on volume. Our subscription offering, giving some good signals, just launching in October, already at over 300 subscribers, moving from 99 to 12 position, since September in the fiber supplement category on Amazon in the UK. And so we expect our focus here to gradually improve revenue and margins, and importantly, set a foundation for some serious near-term growth in the supplements business, which we haven't spoken about, a lot recently. But there's much more to come here over the quarters ahead as we put our new strategy into effect. So I'm gonna close the quarterly and questions there. I can actually see a bunch of additional questions, but I'm mindful of time, so I'm gonna get to them, on Investor Hub. Now for anyone new to Microba, I'll do a quick recap on the business so that you can understand the entire thing and the global opportunity. Let me go there in slides, and let's dive into it. Here we are. I'm gonna dive into who we are, why we exist, our traction, and excitement of what lies ahead, starting with a clear summary of the opportunity. First, why, why does Microba exist? Well, your body is home to trillions of tiny microorganisms, and most of them, about 95%, live in your gut. We call that ecosystem of organisms your gut microbiome, and these tiny organisms are essential for your health. They are so essential that there are now more than 21,000 studies showing that they are key to how we develop and can treat chronic diseases. In fact, there are now over 150 studies demonstrating that if we change these tiny organisms in our gut, that we can improve and even treat chronic diseases from cancer to depression, diabetes, bowel, heart, and many other diseases. From that, we have a clear, global, and ambitious vision that hasn't changed since the beginning of Microba... to realize what we see is set to be a revolution in health, healthcare. A world where first, there's broad acceptance of the microbiome as critical to health and disease management. The second, testing your microbiome is commonplace with your doctor. Third, microbiome therapeutics are approved and routinely used for the maintenance and treatment of multiple chronic diseases, and finally, that leads to millions of patients living healthier lives. Taken together, if microbiome therapeutics and diagnostics indeed play a meaningful role in supporting patients, which we believe they absolutely will, this market opportunity could ultimately be worth more than $1 trillion. This is not theoretical R&D. This is really important. We are commercial stage and already making both of these parts of our vision a reality. For our diagnostic business, opening up a major new diagnostic category, which could be worth more than $100 billion, and our focus today is just on the first $25 billion of that, which is patients with unresolved gastrointestinal disease. We have accelerating traction in our first two markets in Australia and the United Kingdom, delivered, you know, AUD 15.7 million in revenues last year, and we have regional breakeven milestones targeted for FY 2026, aligned to 100% year-on-year growth of our core testing products. For our therapeutics business, we invested in five years of R&D to build a rich pipeline of live biotherapeutic assets. We've completed deep preclinical and early clinical validation, and now in position to harvest the fruits of all that labor and investment. We've transitioned from an R&D and investment phase to a partnering phase, with multiple streams to value return, with deal precedents over $1.5 billion. Multiple recent positive clinical trial readouts, which I just shared before, validating this new drug modality and creating a deal environment which we're in position to leverage. So now let's, let's dive into the products and clinical data. So with the central impact that the microbiome has on a range of diseases, there's a lot of opportunity for Microba, but today, we are laser focused on applying our technology to help patients suffering from gastrointestinal disease. Why? Because it's a ginormous market. It's the biggest piece. There are 82 million people every year across 7 key markets, seeing a doctor with gastrointestinal issues, from severe diarrhea to bloating, pain, irritable bowel syndrome, inflammatory bowel disease. And so the important question is: How do we help these patients in a way that hasn't been possible before? Well, many of the answers for these individuals lie in their gut microbiome. To address that, we have developed two tests. We have MetaPanel for diagnosing gastrointestinal pathogens, which we've launched together with Sonic Healthcare, and we said it's in an early market development phase with gastroenterologists and our clinical study work. And then we have Microbiome Explorer for diagnosing gastrointestinal disorders, which is now launched in both Australia and the United Kingdom. And here you can see the impact of these tests already. So 82 million patients suffering, half of them not getting a resolution with the standard of care. And our real-world data showing that with our tests, we can get critical new diagnosis and treatment recommendations for over 70% of those patients who had previously had no path to a resolution, and then get improved outcomes for over 60% of those already. That's huge. And we've recently put out a raft of high-impact clinical data demonstrating that in thousands of patients, and with multiple studies progressing through the roadmap, we expect a continuation of data further demonstrating and bolstering the clinical utility of these tests. We understand this market intimately. I consistently say that we haven't even scratched the surface of it, and for the avoidance of doubt, here's actually the numbers breaking that down, and this is from deep primary, secondary, and tertiary research, including a large body of work that we did with a Boston-based consulting firm called Veranex. So we have a clear understanding and breakdown of the addressable market, how we target it, slice by slice, bite by bite, and even from the first handful of markets and a focus on one patient population, which is these individuals with unresolved gastrointestinal disorders, we only have to capture a fraction of a% to hit our internal targets over the next three years and be a significant business. We have testimonials now from high-impact clinicians and patients that have been suffering from 10, 20, or even 30 years now, completely resolved after implementing our tests and intervening with a clinician. We're very proud of that, and we see that, you know, every day, every week, every month. So let's dive into our growth model. Our growth strategy, as I shared earlier, is intimately aligned to the adoption curve. So at Microba, we even talk about this internally as the skepticism curve, which has four dimensions to it. On the left, we have the innovator side, where we have, say, an integrative and functional medicine clinician that has low demands of the testing products in terms of interpretability, actionability, business integration, and workflow integration. And then all the way on the right, we have the laggard end, where we would see someone like a very traditional GP, very short on time, being the most skeptical, slow to change, and most challenged in adopting new technology, who have very high demands on interpretability, actionability, business integration, and workflow integration. But the key thing that I want to stress here is that the demand across the vast majority of this spectrum is already strong, stronger than most understand. The clinical importance of the microbiome is accepted, that first part of the vision. It is an essential organ that doctors have missed, and we now see it discussed at almost every clinician conference. The product just now needs to meet the increasing needs from these clinicians as we go from left to right through the adoption and skepticism curve, supported by the aligned evidence that we're developing. The way that we do that is by delivering features one step at a time, from left to right, opening up more and more of that clinician market, addressing their unique needs as we develop the product to serve their practice model and their patients. The team have an incredibly clear product roadmap that they're executing, shipping new features every quarter. You can see what that looks like across these four dimensions, but every quarter, we have significant releases related to interpretability and actionability of the report, as well as features that serve, in particular, these high-volume clinics, which tend to be a key growth driver for this next step of the adoption curve that we've just moved into. In parallel, we believe that brute force sales in medtech is outdated, as, you know, the core growth tactic. It's increasingly ineffective and inefficient. Now, don't get me wrong, sales is critical, an important base layer, but Microba is a unique business in that we have a laboratory in vitro diagnostic component to our product, but the major value unlock is through our medical software stack that sits over the top of it. So, the way that I like to make an analogy here is to say that we have the clinically trusted medical device component. So like a Cochlear is to hearing health, Microba is to gut health. But we also have a sticky clinical software stack that sees us scale more like a medical SaaS company like Pro Medicus. So say, like Pro Medicus is to medical imaging data, Microba is to gut health data. And let's use that as a nice analogy for big names that people know out there in medtech. Aligned to that, we are leveraging a combination of SaaS and medical sales best practice. So as I said before, sales is an important base layer of presence in market, but we're executing what's called a product-assisted and product-led growth system that will continually add on top of sales to reduce customers, customer acquisition cost, increase resource efficiency and shorten sales cycles and time to value. Like, but what does that actually mean in practical terms? That means that rather than a Microba sales specialist having to onboard, train, and support every clinician to be successful with the test and embedded into their routine care protocols for these patients, and just looking at the growth model as number of reps, and then, you know, number of, clinicians and associated volume per rep, that we have a efficient digital system that enables scalable, self-serve onboarding, training, and support, always on, increasingly AI-assisted. We are intensively focused on growth, in conjunction with the underlying unit economics of the business. So we have a clear formula that we're executing, which is laid out here in a customer and market growth metrics going up, together with multiple metrics improving underneath the unit economics and profitability, and you can see that playing out in recent quarters. This drives us in the short term to those regional break-even points in FY 2026, but fast forward a few more years, to break even for the whole company. And finally, we have partnerships with two of the world's largest medical diagnostic companies, which has given us the opportunity to leverage the laboratory networks of these companies so that we don't need to build labs everywhere, and we can scale as a software company, not as a laboratory services company. We recently announced, like last year, we announced our agreement with Sonic's UK business, The Doctors Laboratory, executing exactly that model. We can leverage their large customer networks to efficiently acquire customers, so enabling these partners to refer and triage customers to us to be fully serviced with the world's leading clinical microbiome testing. Finally, there's this attractive additional upside to Microba, leveraging all of the data generated from our diagnostics business and years of R&D and investment. From that data, we have developed this rich pipeline of live therapeutic assets targeting multiple chronic diseases. We've moved from a R&D and investment phase into a partnering focus phase to deliver return on investment. There have been multiple positive clinical readouts over recent months, supporting validation of this new therapeutic modality and creating an environment for deal activity on these assets, and we are ready and in position to capture that deal activity with deal precedence well north of $1.5 billion. We've built an incredible platform for drug discovery from the microbiome, leveraging AI. Taken those assets through deep preclinical and early clinical validation with our lead asset ready to advance into phase two. We have two major pathways to value return on these assets, and there are a range of relevant, deal comps and recent activity. Pathway one here is what we call live biotherapeutics. So this is the traditional drug route, disrupting and advancing standard of care across multiple chronic diseases, with deal precedence ranging between $1.5-$11 billion for new, new modality, related biologics. Pathway 2 is next generation probiotics. So that's disrupting the $79 billion probiotics market with new, healthy, human-derived products. And, and that's advancing from the work that we completed with the world's largest probiotic manufacturer, IFF, International Flavors & Fragrances, listed on the New York Stock Exchange. With deal opportunities there ranging between $50-$100 million. So as I shared earlier, the microbiome therapeutic space, and more specifically, the live biotherapeutic modality, has really been maturing in its development. Many prospective partners have been waiting for these, definitive phase Ib, phase IIa efficacy data readouts that would validate this new live biotherapeutic modality, it particularly in a major chronic disease setting, to then, create the appetite for them to in-license or acquire these assets and add them to their portfolio. Aligned to this, we've been guiding on clinical trial readouts that will provide that modality, validating data for partners and stimulate this broader sector deal activity for these microbiome therapeutic assets, including Microba's best-in-class assets that are, ready and in position to capture this deal activity. There have been multiple recent validating results, particularly since November. Siolta in November first, delivering a successful phase Ib in pediatric allergy disease, a significant result for the sector. MaaT Pharma then in December, delivering a major phase III readout in gastrointestinal acute GVHD, now under regulatory review by the EMA, and with an expected decision later this year. And that's an important one because that stands to be the first potential market approval for a microbiome therapeutic in a chronic, I should say, non-infection setting. And then finally, I was very energized about the EnteroBiotix results in January, delivering a positive phase IIa result in irritable bowel syndrome patients. Because this also plays into, further, advancement in the market, which will feed back to our, our testing business with our focus on unresolved gastrointestinal issues, where IBS is at the center. So we're now awaiting the results, for the last one there on the screen, which is Microbiotica, which is in inflammatory bowel disease. So we've been guiding that with positive readouts, validating the modality, it's reasonable to expect that competitive deal activity could commence, and that deal precedents like the ones I had on the prior, prior slide become a real opportunity. And so we're in position with best-in-class assets, ready to capture those deals. We have seen those results already change the temperature of partnering discussions at the end of the year and into the new year, and be rest assured, we are very active in our partnering work. So I will close by saying, as I always do, I am incredibly excited about the opportunity impacting growth ahead for Microba. We're, we're at a real inflection point of operational focus, advancement up the customer adoption curve, major product advancement and major evidence generation, and AI efficiency and value gains. We have a world-class team, best-in-class technology, and category-defining products. For patients, we're already changing lives. There are a lot of people that need our help, and Microba truly represents a category-defining company with, as I said before, the clinical side of a Cochlear, but with the medical software and scaling opportunity of a Pro Medicus. We have decades of growth to unlock, and it's an incredible time to be a Microba shareholder. So thank you all for listening. If you tuned in and stayed all the way to this point, and importantly, for all of our shareholders, a deep thank you from myself and all the team for your ongoing support. Thank you.